LONDON (AFX) - Provexis PLC said it has entered into a long-term collaboration agreement with Unilever PLC to jointly develop a new concentrated format of its patented Fruitflow heart-health technology for application in Unilever's food product portfolio.

Financial details of the deal were not disclosed.

The partners plan to enter into a global licence arrangement for the technology.

Fruitflow is a patented natural extract from tomato which Provexis said has been shown in human trials to reduce the propensity for aberrant blood clotting that is typically associated with cardiovascular disease and which can lead to heart attack or stroke.

In 2005 the market for heart benefit foods was worth 4 bln usd globally, Provexis added.

Considering the growth potential this share has a target of about 8-10p in the medium tern and is a good buy at current levels

As usual, pls do ur own research.

Well, the much mooted share price collapse, around various boards, to 2.5p hasn't happened yet and with the largest transactions appearing to be buys it would seem those who were allowed to buy at 2.5p are reluctant to part with what they have, or they are selling to those willing to pay above the present odds. I don't know whether I should be excited or apprehensive!

Starting to get a bit pissed off here. With the bloody share price, in the last hour weve had approx 500,000 buys to 30,000 sells and the price is down. Plus heaps more buys than sells nearly daily yet the bloody price keeps falling. Makes no sense.

regardless of that, it seems to me that until PXS can get EU approval, which clearly they have not yet got, they will get no licencing deals finalised, and thus sp will continue to drift ...... all other claims as to Fruitflow's efficacy etc are as good as those for snakeoil

Blanche, why pissed off? What percentage is a mere 500k of the total issued capital? I daresay not very much - probably less than 1%. Unless startling news of a confirmed tie up, resulting in profits to the bottom line, SP will continue to drift. The company isn't worth its SP, fullstop..........

(I guess you're pissed off because you could have sold at a much higher price and banked a more than decent profit). Maybe there's hope yet??

Again buys outweighing sells 3 to 1 approx. Edit 4 to 1

Pth, No not pissed off about banking profits. Happy for my free running shares to go the course.

26/10/09 11:44 22.0 145,625 O 6.3 6.49 Buy 3,067,878 1,050,514

Answers on a postcard

Sold a big chuck of my holding, still a believer, but will buy back in on the first signs of news. Seems a good time to sell as not sure of markets at mo. have also sold some decent chucks in other comps to. Could be a good time to hold some cash.

could be a good time to wear a tin hat and to dig latrines as well as trenches ..... glad i dumped yesterday at 6.25

Fruitflow European Health Claim Update (Provexis)





TIDMPXS

RNS Number : 7995B
Provexis PLC
03 November 2009

?


Provexis plc ("Provexis" or the "Company")


Update on European Commission authorisation of health claim wording for
Fruitflow


Provexis, the life-science business that discovers, develops and licenses
scientifically-proven functional food, medical food and dietary supplement
technologies, is pleased to announce an update on the authorisation process by
the European Commission for the use of a health claim for the Company's
Fruitflow anti-thrombotic technology.


The Company announced on 28 May 2009, that Fruitflow was the first technology
to have a health claim approved by the European Food Safety Authority under
Article 13(5) of Regulation (EC) No 1924/2006 on nutrition and health claims
made on foods. As previously announced, the European Commission has since been
in an ongoing period of review, as it considers the health claim wording
for Fruitflow which may be used on end consumer products under the Regulation.


The Company has been in regular contact with the European Commission throughout
this period and confirms that it has been informed that the process is now in an
advanced stage. An announcement will be made to the market as soon as the
conclusion of the process has been notified to the Company.


3 November 2009


For further information please contact:


Provexis plc Tel: 01753 752290
Stephen Moon, Chief Executive


Evolution SecuritiesTel: 0207 071 4300
Sam Plumptre
Bobbie Hilliam




Notes to Editors


About Fruitflow


Provexis' development of Fruitflow , a water-soluble tomato concentrate, is a
breakthrough in anti-thrombotic food technology. In human trials, consumption
of the Fruitflow extract has been proven to reduce platelet aggregation in 97%
of subjects. The effect takes place within three hours of consumption and lasts
for up to eighteen hours, making it ideal for daily dosage in functional foods
or dietary supplements. Provexis has developed a syrup format for use in food &
beverages and a concentrated powder format for tablets and capsules.


Fruitflow syrup is GRAS (Generally Regarded as Safe) by the US FDA and is not
regarded as a Novel Food in the EU, clearing it for wide use in foods, beverages
and supplements. In May 2009, the Fruitflow technology was the first to be
substantiated by the European Food Safety Authority ("EFSA") under the new
Article 13(5) for proprietary and emerging science.


The technology has been granted patents in the EU, US, Australia, Canada and
Mexico, with Japan pending. Further patents have been filed for the bioactive
components of Fruitflow and for other developmental areas such as deep vein
thrombosis and triglyceride lowering.








About Provexis plc


AIM-listed Provexis is focused on the discovery, development and licensing of
technologies for the functional food, dietary supplement and medical food
sectors.


The company was originally spun out of the Rowett Institute (now part of the
University of Aberdeen) in 1999 to commercialise their tomato extract discovery
using venture capital funding. Provexis Limited was reversed into Nutrinnovator
in 2005 and its major investors are DSM Venturing and Rising Stars Growth Fund
(part of Enterprise Ventures).


The company has additional biotechnology developments, including a joint venture
with the University of Liverpool to develop an extract of plantain which aids
the treatment of inflammatory bowel disease, and an early stage technology under
option from University of Manchester for the prevention and treatment of peptic
ulcers.

This information is provided by RNS
The company news service from the London Stock Exchange
END

MSCBTBFTMMMMBPL

Well I made another quick buck on the fruity thing here as I was already in...took the profit this morning...I don't like this stock (as yet) but that's the third time I've made a small profit.

Not long now!

it would seem the slightest bit of news will send this up. holding on tight.

how high does everybody think this will go ?????

Kosyboy, 10-12p on offically confirmation of wording. 20p on first deal. Then who knows aimvho. But please dyor.

Blanche, when can you see this happening

Kosyboy, I would hope confirmation would now be very soon as talks are now in advanced stages, and i think deals are probally already done, just waiting for confirmation. imvho.

Out rest of day antiques auction to go to.

make sure you don't get sold off

Bet you wish you'd now kept them though cynic even allowing for their high risk.

bought back 50k yesterday at 7.21

In that case cynic, you have given me hope that the sp will travel in a northerly direction so that I can make a nice little profit!